ClinicalTrials.gg
Not yet recruitingNCT07325591Updated Sep 10, 2026

Efficacy and Safety of Tazbentetol in ALS Participants

A Phase 2/3 interventional study of Tazbentetol and placebo in Amyotrophic Lateral Sclerosis, sponsored by Spinogenix. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Spinogenix · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
430
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The objectives of this study are to examine the effects of tazbentetol on clinical measures of ALS, patient reported outcomes (PROs), long-term safety and tolerability.

Read the detailed description

This is a Phase 2B/3 adaptive design randomized, double-blind, placebo-controlled (DBPC) study to evaluate the efficacy, safety and tolerability of tazbentetol administered orally in participants with ALS.

The study consists of 2 parts, as follows

Phase 2 double-blind, placebo controlled (DBPC): Randomized, double-blind, placebo-controlled study. Participants will be randomized to receive tazbentetol or placebo for 36 weeks.

Phase 3 double blind, placebo controlled (DBPC): Randomized, double-blind, placebo-controlled study. Participants will be randomized to receive the dose determined from Phase 2 or placebo for 36 weeks.

Open-label extension: Eligible participants who complete 36 weeks in the DBPC of either Phase 2 or Phase 3 will be offered to enroll into the OLE, starting at the corresponding DBPC Week 36 visit, and receive tazbentetol for 36 weeks. The dose for this extension will be based on data from DBPC phases.

02

Conditions studied

  • Amyotrophic Lateral Sclerosis

Keywords

  • regenerative
  • synapse
  • Amyotrophic Lateral Sclerosis
  • placebo-controlled
03

In context

Amyotrophic Lateral Sclerosis

980 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 279 are open to participants now.

This study's planned enrollment of 430 is above the median of 38 across 664 interventional studies indexed under Amyotrophic Lateral Sclerosis.

Browse Amyotrophic Lateral Sclerosis studies →

Lead sponsor

Spinogenix is the lead sponsor of 9 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-80
  • ALS TRICALS risk score
  • Stable dose of standard of care treatment
  • use by men or women consistent with local regulations
  • Able and willing to provide written

Exclusion criteria

Exclusion Criteria:

  • Underlying physical or psychological condition prohibiting study completion
  • cardiac disease
  • Active or history of in the past 5 years
  • Serious infection within 1 month of screening
  • Acute illness within 30 days of Day 1
  • History of suicidal behavior or suicidal ideation
  • Active cigarette smokers and users of nicotine-containing products
  • Neurodegenerative disease
  • External respiratory support or supplemental oxygen requirement
  • , and positive
  • Vaccines within 14 days
  • Other products within 30 days
  • Blood donation within 30 days
  • Plasma donation within 7 days
  • Pregnant or breastfeeding
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
430 participants (estimated)

Study arms

  • Experimental
    tazbentetol

    synthetic small molecule

    Drug: Tazbentetol

  • Placebo comparator
    Placebo

    placebo

    Drug: placebo

Interventions

  • Participants in both Phase 2B and Phase 3 will be randomized to received study drug tazbentetol or placebo tablets. Participants in the open-label extension phase will receive the dose determined from Phase 2.

    Also known as: SPG302

  • Drugplacebo

    participants in double blind placebo controlled phase will be randomized to received placebo tablets

06

What researchers measure

Primary outcomes

  1. Phase 2: Absolute change from baseline in Amyotrophic Lateral Sclerosis Functional Rating Scale-revised (ALSFRS-R) total score

    Questionnaire administered by a clinician that measures participants' ability to function in certain daily activities. Each type of function is scored from 4 (normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0. Patients with higher scores have more physical function.

    Time frame: 36 weeks

  2. Phase 3: Absolute change from baseline in Amyotrophic Lateral Sclerosis Functional Rating Scale-revised (ALSFRS-R) total score

    Questionnaire administered by a clinician that measures participants' ability to function in certain daily activities. Each type of function is scored from 4 (normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0. Patients with higher scores have more physical function.

    Time frame: 36 weeks

  3. OLE: Absolute change from baseline in Amyotrophic Lateral Sclerosis Functional Rating Scale-revised (ALSFRS-R) total score

    Questionnaire administered by a clinician that measures participants' ability to function in certain daily activities. Each type of function is scored from 4 (normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0. Patients with higher scores have more physical function.

    Time frame: 36 weeks

Secondary outcomes

  1. Phase 2: Combined Assessment of Function and Survival (CAFS) scores

    This assessment ranks clinical outcome based on changes to ALSFRS-R score. A higher score indicates a better clinical outcome.

    Time frame: 36 weeks

  2. Phase 2: Change from baseline in Clinician Global Impression-Inhibitory (CGI-I)

    Change in clinician rated measures on scale of 1 to 7, higher value indicates more severe symptom presentation

    Time frame: 36 weeks

  3. Phase 2: Change from baseline in Edinburgh Cognitive and Behavioural ALS Screen (ECAS)

    Questionnaire to assesses cognitive and behavioral changes in people with (ALS) through a 136-point test covering language, verbal fluency, executive function, memory, and visuospatial cognitive domains. A lower score indicates worsening of symptoms.

    Time frame: 36 weeks

  4. Phase 2: Change from baseline in ALS Assessment Questionnaire 40 items (ALSAQ-40)

    The ALSAQ40 score is a measure of QoL for patients with ALS. The ALSAQ40 evaluates domains that include physical mobility, activities of daily living (ADL) and independence, eating and drinking, communication, and emotional reactions. A higher score indicates higher disability.

    Time frame: 36 weeks

  5. Phase 2: Change from baseline in Patient Global Impression (PGI) of Improvement

    This will measure all aspects of patient health and improvement or decline. A higher scale indicates greater disability.

    Time frame: 36 weeks

  6. Phase 2: Change from baseline in Rasch Overall ALS Disability (ROADS).

    This will measure patient reported outcomes of overall disability. A lower score indicates greater disability.

    Time frame: 36 weeks

  7. Phase 2: Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)

    This will assess the safety and tolerability of tazbentetol in of participants with ALS

    Time frame: 36 weeks

  8. Phase 3: Combined Assessment of Function and Survival (CAFS) scores

    This assessment ranks clinical outcome based on changes to ALSFRS-R score. A higher score indicates a better clinical outcome.

    Time frame: 36 weeks

  9. Phase 3: Change from baseline in Clinician Global Impression-Inhibitory (CGI-I)

    Change in clinician rated measures on scale of 1 to 7, higher value indicates more severe symptom presentation

    Time frame: 36 weeks

  10. Phase 3: Change from baseline in Edinburgh Cognitive and Behavioural ALS Screen (ECAS)

    Questionnaire to assesses cognitive and behavioral changes in people with (ALS) through a 136-point test covering language, verbal fluency, executive function, memory, and visuospatial cognitive domains. A lower score indicates worsening of symptoms.

    Time frame: 36 weeks

  11. Phase 3: Change from baseline in ALS Assessment Questionnaire 40 items (ALSAQ-40)

    The ALSAQ40 score is a measure of QoL for patients with ALS. The ALSAQ40 evaluates domains that include physical mobility, activities of daily living (ADL) and independence, eating and drinking, communication, and emotional reactions. A higher score indicates higher disability.

    Time frame: 36 weeks

  12. Phase 3: Change from baseline in Patient Global Impression (PGI) of Improvement

    This will measure all aspects of patient health and improvement or decline. A higher scale indicates greater disability.

    Time frame: 36 weeks

  13. Phase 3: Change from baseline in Rasch Overall ALS Disability (ROADS).

    This will measure patient reported outcomes of overall disability. A lower score indicates greater disability.

    Time frame: 36 weeks

  14. Phase 3: Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)

    This will assess the safety and tolerability of tazbentetol in of participants with ALS

    Time frame: 36 weeks

  15. OLE: Combined Assessment of Function and Survival (CAFS) scores

    This assessment ranks clinical outcome based on changes to ALSFRS-R score. A higher score indicates a better clinical outcome.

    Time frame: 36 weeks

  16. OLE: Change from baseline in Clinician Global Impression-Inhibitory (CGI-I)

    Change in clinician rated measures on scale of 1 to 7, higher value indicates more severe symptom presentation

    Time frame: 36 weeks

  17. OLE: Change from baseline in ALS Assessment Questionnaire 40 items (ALSAQ-40)

    The ALSAQ40 score is a measure of QoL for patients with ALS. The ALSAQ40 evaluates domains that include physical mobility, activities of daily living (ADL) and independence, eating and drinking, communication, and emotional reactions. A higher score indicates higher disability.

    Time frame: 36 weeks

  18. OLE: Change from baseline in Edinburgh Cognitive and Behavioural ALS Screen (ECAS)

    Questionnaire to assesses cognitive and behavioral changes in people with (ALS) through a 136-point test covering language, verbal fluency, executive function, memory, and visuospatial cognitive domains. A lower score indicates worsening of symptoms.

    Time frame: 36 weeks

  19. OLE: Change from baseline in Patient Global Impression (PGI) of Improvement

    This will measure all aspects of patient health and improvement or decline. A higher scale indicates greater disability.

    Time frame: 36 weeks

  20. OLE: Change from baseline in Rasch Overall ALS Disability (ROADS).

    This will measure patient reported outcomes of overall disability. A lower score indicates greater disability.

    Time frame: 36 weeks

  21. OLE: Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)

    This will assess the safety and tolerability of tazbentetol in of participants with ALS

    Time frame: 36 weeks

Other outcomes

  1. Phase 2: ALSFRS-R total score rate of decline

    To further assess the effect of tazbentetol on the progression of ALS

    Time frame: 36 weeks

  2. Phase 2: Proportion of patients alive and survival time

    To further assess the effect of tazbentetol on the progression of ALS

    Time frame: 36 weeks

  3. Phase 2 substudy: To compare electroencephalogram (EEG) outcomes of two dose levels of tazbentetol to placebo in participants with ALS

    To measure the change from baseline in EEG delta and power bands at resting state at Weeks 8, 24, and 36

    Time frame: 36 weeks

  4. Phase 3: ALSFRS-R total score rate of decline

    To further assess the effect of tazbentetol on the progression of ALS

    Time frame: 36 weeks

  5. Phase 3: Proportion of patients alive and survival time

    To further assess the effect of tazbentetol on the progression of ALS

    Time frame: 36 weeks

  6. OLE: ALSFRS-R total score rate of decline

    To further assess the effect of tazbentetol on the progression of ALS

    Time frame: 36 weeks

  7. OLE: Proportion of patients alive and survival time

    To further assess the effect of tazbentetol on the progression of ALS

    Time frame: 36 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Dec 2027, 14 months later.

Of 22 phase 2/3 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 109. This study's planned 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2026
First posted
Jan 8, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Mar 1, 2028
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07325591
Lead sponsor
Spinogenix
Responsible party
Sponsor
First posted
Jan 8, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Mar 1, 2028 (estimated)
Last update
Sep 10, 2026

Study contacts

Study Contact
Contact
contact@spinogenix.com
503 915 1400

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SPG-302

Start the discussion